@article {Carnevale303, author = {Joseph Anthony Carnevale and Jacob Goldberg and Gary Kocharian and Maricruz Rivera and Alexandra Giantini Larsen and Andrew Garton and Alexander Ramos and Jasmine H Francis and David H Abramson and Y Pierre Gobin}, title = {Intra-arterial chemotherapy for retinoblastoma}, volume = {15}, number = {3}, pages = {303--304}, year = {2023}, doi = {10.1136/neurintsurg-2022-018957}, publisher = {British Medical Journal Publishing Group}, abstract = {Intra-arterial chemotherapy (IAC) for retinoblastoma is a minimally invasive and chemotherapeutic approach resulting in eye salvage and vision restoration or preservation. Moreover, IAC has proven to effectively treat advanced retinoblastoma while not compromising patient survival. Our institutional experience with IAC for retinoblastoma has included over 500 patients and over 2400 intra-arterial infusions. Each infusion is completed with the use of a micropuncture for arterial access and microcatheter for infusion, eliminating the need for guide catheters and related complications (video 1). This treatment modality has resulted in \>95\% ocular survival and reduces enucleation to \<5\% for this population. In addition to local therapy, including cryotherapy, intravitreal chemotherapy, or laser treatments, by the ophthalmologist, IAC has become an important component of comprehensive multidisciplinary and multimodal therapy for this disease. For what used to require a possibly vision-sacrificing procedure, retinoblastoma treated with IAC minimizes the need for enucleation while maximizing both patient and ocular survival.Supplementary data [neurintsurg-2022-018957supp001.pdf] Video 1 }, issn = {1759-8478}, URL = {https://jnis.bmj.com/content/15/3/303}, eprint = {https://jnis.bmj.com/content/15/3/303.full.pdf}, journal = {Journal of NeuroInterventional Surgery} }